<DOC>
	<DOCNO>NCT00443326</DOCNO>
	<brief_summary>Investigational drug AMG 714 give 66 subject moderate severe psoriasis study safety , pharmacokinetics , efficacy . Dose level include 150mg 300mg give subject total 6 dos . Each dose subject give every 2 week . Subjects follow 300 day post first dose AMG 714 .</brief_summary>
	<brief_title>AMG 714 20060349 Multiple Dose Study Moderate Severe Psoriasis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Active clinically stable , plaque psoriasis . Psoriasis involve great equal 10 % body surface area A minimum PASI score 10 obtained screen period . Received least one previous phototherapy systemic psoriasis therapy candidate receive phototherapy systemic psoriasis therapy opinion investigator . At least 18 year age . Heterosexually active men woman must willing practice effective method contraception ( outlined section 6.7 ) determine investigator sponsor duration study . This include washout period followup period . ALT AST less equal 2 x upper limit normal ; hemoglobin great equal 10 g/dL ( great equal 100 g/L SI unit ) ; platelet count great equal 125,000 mm3 ( great equal 125 x109/L SI unit ) ; white blood cell count great equal 3,500 cells/mm3 ( great equal 3.5 x109/L SI unit ) ; serum creatinine less equal 2 mg/dL ( less equal 177 Î¼mol/L SI unit ) . Negative HIV antibody , hepatitis B surface antigen , hepatitis C antibody . Capable understanding give write , voluntary inform consent study screen . Active guttate , erythrodermic , pustular psoriasis time screen visit . Evidence skin condition ( eg , eczema ) time screen visit screen visit study drug initiation would interfere evaluation effect investigational product psoriasis . Clinically significant adverse event , infection , laboratory toxicity , time screen visit screen visit study drug initiation opinion Amgen Investigator would preclude participation study . Clinically significant infection less equal 30 day screen visit opinion Amgen Investigator would preclude participation study . Known positive tuberculin skin test ( treated appropriate chemoprophylaxis ) recent ( within 6 month ) exposure patient active tuberculosis . Any known infectious process would , investigator 's discretion , interfere subject 's ability participate study . Significant concurrent medical condition time screening , include : Uncontrolled hypertension ( define screen systolic blood pressure measurement great 160 mm Hg screen diastolic blood pressure great 100 mm Hg ) confirm 2 separate measurement screen visit Myocardial infarction less equal 52 week screen visit Unstable angina pectoris Congestive heart failure Steroid oxygen dependent chronic obstructive pulmonary disease Diagnosis multiple sclerosis demyelinate disease Inadequately control diabetes mellitus , define glycohemoglobin great 7.0 screen History cancer ( resect surgically cured cervical cancer , cutaneous basal cell , squamous cell carcinoma ) less equal 5 year administration first dose investigational product Open cutaneous ulcer Any condition , judgment investigator , might cause study detrimental subject . Any evidence screen cutaneous basal squamous cell carcinoma , melanoma . Current history psychiatric disease would interfere ability comply study protocol give informed consent . History alcohol drug abuse would interfere ability comply study protocol . Previous receipt etanercept antiTNF agent ( ) , alefacept , efalizumab , investigational biologic agent psoriasis . Receipt investigational product ( ) less equal 30 day first dose investigational product study . PUVA therapy less equal 30 day first dose investigational product . UVA therapy less equal 14 day first dose investigational product . UVB therapy less equal 30 day first dose investigational product . Receipt systemic psoriasis therapy oral parenteral corticosteroid less equal 14 day first dose investigational product . Topical steroid , topical vitamin A D analog preparation anthralin less equal 14 day first dose investigational product ( exception topical steroid higher moderate strength , accord package insert , permit scalp , axilla , groin ) . Topical cyclosporin calcineurin inhibitor pimecrolimus ( Elidel ) tacrolimus ( Protopic ) less equal 14 day first dose investigational product . Intravenous oral calcineurin inhibitor tacrolimus ( Prograf ) less equal 30 day first dose investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>PASI</keyword>
	<keyword>Skin Biopsy</keyword>
	<keyword>Human Monoclonal Antibody</keyword>
</DOC>